Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Molinelli, A. Campanati, V. Brisigotti, A. Offidani (2018)
Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.Current pharmaceutical biotechnology, 18 12
(Truven Health Analytics. Red Book. Ann Arbor, MI. http://www.micromedexsolutions.com/micromedex2/librarian/. Accessed 27 Mar 2018.)
Truven Health Analytics. Red Book. Ann Arbor, MI. http://www.micromedexsolutions.com/micromedex2/librarian/. Accessed 27 Mar 2018.Truven Health Analytics. Red Book. Ann Arbor, MI. http://www.micromedexsolutions.com/micromedex2/librarian/. Accessed 27 Mar 2018., Truven Health Analytics. Red Book. Ann Arbor, MI. http://www.micromedexsolutions.com/micromedex2/librarian/. Accessed 27 Mar 2018.
Jashin Wu, S. Feldman, S. Rastogi, B. Menges, M. Lingohr-Smith, Jay Lin (2018)
Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United StatesJournal of Dermatological Treatment, 29
A. Carvalho, R. Duquia, B. Horta, R. Bonamigo (2016)
Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsDrugs in R&D, 17
Elizabeth Brezinski, J. Dhillon, A. Armstrong (2015)
Economic Burden of Psoriasis in the United States: A Systematic Review.JAMA dermatology, 151 6
K. Papp, K. Gordon, R. Langley, M. Lebwohl, A. Gottlieb, S. Rastogi, R. Pillai, R. Israel (2018)
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3British Journal of Dermatology, 179
A. Menter, K. Papp, M. Gooderham, D. Pariser, M. Augustin, F. Kerdel, S. Fakharzadeh, K. Goyal, S. Calabro, W. Langholff, S. Chavers, D. Naessens, J. Sermon, G. Krueger (2016)
Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Journal of the European Academy of Dermatology and Venereology, 30
W. Tausend, C. Downing, S. Tyring (2014)
Systematic Review of Interleukin-12, Interleukin-17, and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque PsoriasisJournal of Cutaneous Medicine and Surgery, 18
C. Asche, Minchul Kim, S. Feldman, P. Zografos, Minyi Lu (2017)
Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costsJournal of Medical Economics, 20
(Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018. 10.1111/bjd.16464)
Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018. 10.1111/bjd.16464Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018. 10.1111/bjd.16464, Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018. 10.1111/bjd.16464
(Stelara (ustekinumab). Full Prescribing Information. Janssen Pharmaceutical Companies. 2017. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf. Accessed 20 Apr 2018.)
Stelara (ustekinumab). Full Prescribing Information. Janssen Pharmaceutical Companies. 2017. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf. Accessed 20 Apr 2018.Stelara (ustekinumab). Full Prescribing Information. Janssen Pharmaceutical Companies. 2017. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf. Accessed 20 Apr 2018., Stelara (ustekinumab). Full Prescribing Information. Janssen Pharmaceutical Companies. 2017. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf. Accessed 20 Apr 2018.
F. Hjalte, K. Carlsson, Marcus Schmitt-Egenolf (2015)
Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic AgentDermatology, 230
RB Warren, CH Smith, ZZ Yiu (2015)
Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)J Invest Dermatol, 135
(2018)
Impact of previous biologic use on efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: Integrated analysis of AMAGINE-2 and AMAGINE-3
R. Stern, T. Nijsten, S. Feldman, D. Margolis, T. Rolstad (2004)
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.The journal of investigative dermatology. Symposium proceedings, 9 2
T. Gu, N. Shah, G. Deshpande, D. Tang, D. Eisenberg (2016)
Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort StudyDrugs - Real World Outcomes, 3
L. Naldi, S. Mercuri (2010)
Epidemiology of comorbidities in psoriasisDermatologic Therapy, 23
(Siliq (brodalumab). Full Prescribing Information. Valeant Pharmaceuticals. 2017. http://www.valeant.com/Portals/25/Pdf/PI/Siliq-pi.pdf. Accessed 20 Apr 2018.)
Siliq (brodalumab). Full Prescribing Information. Valeant Pharmaceuticals. 2017. http://www.valeant.com/Portals/25/Pdf/PI/Siliq-pi.pdf. Accessed 20 Apr 2018.Siliq (brodalumab). Full Prescribing Information. Valeant Pharmaceuticals. 2017. http://www.valeant.com/Portals/25/Pdf/PI/Siliq-pi.pdf. Accessed 20 Apr 2018., Siliq (brodalumab). Full Prescribing Information. Valeant Pharmaceuticals. 2017. http://www.valeant.com/Portals/25/Pdf/PI/Siliq-pi.pdf. Accessed 20 Apr 2018.
(Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Psoriasis update: draft evidence report. 27 Apr 2018. Boston, MA. https://icer-review.org/wp-content/uploads/2017/11/ICER_Psoriasis_Update_Draft_Report_04272018.pdf. Accessed 30 Apr 2018.)
Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Psoriasis update: draft evidence report. 27 Apr 2018. Boston, MA. https://icer-review.org/wp-content/uploads/2017/11/ICER_Psoriasis_Update_Draft_Report_04272018.pdf. Accessed 30 Apr 2018.Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Psoriasis update: draft evidence report. 27 Apr 2018. Boston, MA. https://icer-review.org/wp-content/uploads/2017/11/ICER_Psoriasis_Update_Draft_Report_04272018.pdf. Accessed 30 Apr 2018., Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Psoriasis update: draft evidence report. 27 Apr 2018. Boston, MA. https://icer-review.org/wp-content/uploads/2017/11/ICER_Psoriasis_Update_Draft_Report_04272018.pdf. Accessed 30 Apr 2018.
P. Kerkhof (2005)
Handbook of Dermatology drug therapy.Journal of Dermatological Treatment, 16
V. Strand, E. Husni, J. Griffith, Zheng-Yi Zhou, J. Signorovitch, A. Ganguli (2016)
Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the USRheumatology and Therapy, 3
Full Prescribing Information. Valeant Pharmaceuticals
C. Choi, J. Choi, B. Kim, S. Youn (2018)
Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe PsoriasisAnnals of Dermatology, 30
W Tausend, C Downing, S Tyring (2014)
Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumabJ Cutan Med Surg, 18
M. Lebwohl, B. Strober, A. Menter, K. Gordon, J. Węgłowska, L. Puig, K. Papp, L. Spelman, D. Toth, F. Kerdel, A. Armstrong, G. Stingl, A. Kimball, H. Bachelez, Jashin Wu, J. Crowley, R. Langley, T. Blicharski, C. Paul, J. Lacour, S. Tyring, L. Kircik, S. Chimenti, K. Duffin, J. Bagel, J. Koo, G. Aras, Joanne Li, Wenjie Song, Cassandra Milmont, Yifei Shi, N. Erondu, P. Klekotka, B. Kotzin, A. Nirula (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.The New England journal of medicine, 373 14
Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Psoriasis update: draft evidence report
S. Kurd, J. Gelfand (2009)
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.Journal of the American Academy of Dermatology, 60 2
IntroductionClinical trials have shown brodalumab to have better efficacy than ustekinumab for the treatment of moderate-to-severe psoriasis. An estimation of the cost-effectiveness of brodalumab vs. ustekinumab is warranted and may be useful for treatment decision-making processes, especially in the context of the cost considerations of the current US healthcare system. Therefore, we compared the cost-effectiveness of brodalumab with ustekinumab for treatment of moderate-to-severe psoriasis in biologic-naïve and biologic-experienced patients in the USA.MethodsAn Excel-based economic model was developed to estimate and compare total annual costs to health plans associated with treatment with brodalumab vs. ustekinumab per achievement of Psorasis Area and Severity Index (PASI) 75, 90, and 100 for patients with moderate-to-severe psoriasis.ResultsFor treatment with brodalumab vs. ustekinumab, total annual treatment costs per PASI 75, 90, and 100 were $31,106, $57,776, and $163,069, respectively, lower for a patient naïve to prior biologic treatment; they were $40,535, $65,472, and $223,610, respectively, lower for a patient experienced with prior biologic treatment. In an additional analysis among patients with and without prior biologic failure, they were $52,822, $93,309, and $365,606, respectively, lower for a patient with failure and they were $31,660, $57,128, and $164,996, respectively, lower for a patient without failure.ConclusionCompared to ustekinumab, treatment with brodalumab was associated with better cost-effectiveness ratios for biologic-naïve and experienced-patients and also patients with and without prior biologic treatment failure. The greater cost-effectiveness of brodalumab was most prominent for biologic-experienced and prior biologic treatment failure patients.FundingOrtho Dermatologics.
Dermatology and Therapy – Pubmed Central
Published: Jul 13, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.